Biogen Idec To Commercialize Biosimilars Under Samsung Bioepis JV
This article was originally published in PharmAsia News
Executive Summary
Biogen Idec will exercise its right to commercialize anti-TNF biosimilar product candidates in Europe under a JV inked with South Korea’s Samsung BioLogics to develop biosimilars.